ifnα 1

IFNα-IN-1 (AJ2-18) is an inhibitor of IFNα, capable of suppressing the production of IFN-α. It is applicable in inflammation research.

GSK2245035 is a highly selective intranasal TLR7 agonist with preferential Type-1 interferon (IFN)-stimulating properties (pEC50s: 9.3 and 6.5 for IFNα and TFNα). It effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood

BNT411, a selective TLR7 agonist, induces IFNα release both in vivo and in vitro. With anticancer activity, BNT411 is applicable in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC) [1].

Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].

IFN-α Receptor Recognition Peptide 1, associated with receptor interactions, is a peptide of IFN-α.